SPEECH-PROCESSING-SOLUTI
27.9.2016 09:06:23 CEST | Business Wire | Press release
Speech Processing Solutions , the world number 1 for professional dictation solutions , is proud to announce very positive feedback on its latest voice recorder, the Philips SpeechAir, and the SpeechLive cloud solution, which now also offers speech recognition.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160927005172/en/
Both SpeechAir and SpeechLive are ideally suited to professionals who are often on the move and do not always work from their usual office workplace. Ingo Bischof, MBA, Managing Director of IVAM Real Estate, is delighted with the advantages of these two solutions: "With Philips dictation solutions it is possible for us to log and record issues in the properties that we maintain significantly more quickly. The recordings are then sent to our back office, saving us a considerable amount of time, as transcription can begin before we return to the office."
Exceptional recording quality and intuitive slide switch recording control
The SpeechAir is equipped with three professional-quality microphones providing ultimate sound quality in any recording situation . Background noise is filtered and the voices are recorded in perfect quality. This ensures excellent playback and speech recognition results. At the start of the year, the SpeechAir was awarded Nuance Communications' rating for best recording accuracy . The slide switch provides an efficient and intuitive user interface operated with just one hand. Recordings can be started, paused, stopped, played back, rewound and fast-forwarded using the slide switch .
Stay connected with the Wi-Fi and Bluetooth functions
The Wi-Fi and Bluetooth connections allow wireless transfer of finished recordings and access to the customer's data in the respective document management system, email or calendar. Dr Doris Ulreich-Laussermayer, a doctor in obstetrics and gynaecology, appreciates this function. "I can send additions to the PC in the medical practice via Wi-Fi on the move or from home and my assistant can edit them. Another thing that I especially like about SpeechAir is its portability, as I can move freely around the practice. The SpeechAir's antimicrobial surface is another positive aspect for hygiene in my medical practice," says the doctor.
SpeechLive speech recognition – speak, send, receive the finished document
The Philips SpeechLive cloud dictation solution now includes speech recognition available in 21 languages. Spoken words are converted into a written text in next to no time. SpeechLive can be used at any time and is easily accessible via any web browser with no software installation required. "Our company is split between two different locations. Last week I was working in the office in Melbourne; this week I am outside of the city in Mount Waverley. It's great to be able to work from anywhere, without having to think about taking something with me. I can sign in from any computer," raves Nicole Honan, Office Manager at the law firm Hicks Oakley Chessell Williams in Australia.
For more information about our solutions visit:
About Speech Processing Solutions
Speech Processing Solutions is the global leader in professional dictation solutions. The company was founded in 1954 in Austria as a Philips subsidiary, and has been a driving force for innovative speech-to-text solutions for 60 years. The company developed ground-breaking products such as the mobile Philips SpeechAir , the Philips Pocket Memo voice recorder , the Philips SpeechMike Premium USB dictation microphone and the Philips Dictation Recorder app for smartphones, thus meeting its demands for excellence and superior quality. Thanks to the newest innovation, Philips SpeechLive , dictations and recordings will become faster and easier than ever before with cloud-based workflow services. Speech Processing Solution's perfectly tailored offers and products help professionals save time and resources and maximize efficiency.
Connect with Speech Processing Solutions on:
Facebook: http://www.facebook.com/philipsvoicetracer
Instagram: https://www.instagram.com/philips_dictation/
Twitter @speech_com: http://www.twitter.com/speech_com
YouTube: http://www.youtube.com/philipsdictation
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
View source version on businesswire.com: http://www.businesswire.com/news/home/20160927005172/en/
Contact:
Speech Processing Solutions
Christina Angerer
christina.angerer@speech.com
Tel:
+43 1605 291 488
www.philips.com/dictation
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom